Full history for every metric is available with a Kvantra account
Stock profile
Asarina Pharma AB (publ) (ASRPF)
Current price
2.45 USD0.00%
Last close 23 May 2023Benchmarks
Key financial summary
Financials in SEK| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 3 | 5 | 7 | 17 | 39 | 23 | 22 |
| Operating profit | SEK m | 4 | 3 | |||||
| Net profit | SEK m | -0 | -0 | 0 | 1 | 3 | 3 | 2 |
| EPS reported | SEK | 0.09 | 0.08 | |||||
| Operating cashflow per share | SEK | 0.08 | 0.08 | |||||
| Capex per share | SEK | 0.00 | 0.00 | |||||
| FCF per share | SEK | 0.08 | 0.08 | |||||
| Free cash flow | SEK m | 2 | 1 | |||||
| Net debt | SEK m | -4 | -2 | |||||
| Book value equity | SEK m | 14 | 14 | |||||
| Book value per share | SEK | 0.46 | 0.48 | |||||
| Number of shares | m | 29.73 | 29.78 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 274.70 | - | |||||
| P/B LTM | x | 54.60 | 29.13 | |||||
| P/S LTM | x | 32.51 | 18.69 | |||||
| P/FCF LTM | x | 311.09 | 409.42 | |||||
| EV/EBITDA LTM | x | 186.61 | 121.34 | |||||
| EV/Sales LTM | x | 32.34 | 18.61 | |||||
| Earnings Yield LTM | % | 0.36% | 0.38% | |||||
| FCF Yield | % | 0.32% | 0.24% | |||||
| Quality | ||||||||
| ROE | % | 19.98% | 21.43% | |||||
| ROIC | % | 20.90% | 20.90% | |||||
| Operating margin | % | 15.90% | 15.90% | |||||
| Gross margin | % | 44.57% | 44.57% | |||||
| FCF/Sales | % | 10.45% | 10.45% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -7.00% | -33.95% | |||||
| Sales Growth YoY | % | -41.38% | -46.46% | |||||
| Net Income Growth YoY | % | -9.43% | -34.06% | |||||
| FCF Growth | % | -39.08% | -79.06% | |||||
| Operating Profit Growth | % | -1.64% | -32.86% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | -0.99 | -0.99 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -0.53% | -0.43% | |||||
| Net debt/Equity | x | -0.29 | -0.13 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
No description available.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
AS
Asarina Pharma AB (publ) (ASRPF)
ASRPF · OTC · Healthcare
2.45 USD0.00%
Benchmarks
Financialsin SEK
20212022TTM
Total revenue SEK m392322
Operating profit SEK m43
Net profit SEK m332
EPS reported SEK0.090.08
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free